Back to Journals » Biologics: Targets and Therapy » Volume 3

Palifermin for management of treatment-induced oral mucositis in cancer patients

Authors Barasch A, Epstein J, Tilashalski K

Published 16 February 2009 Volume 2009:3 Pages 111—116

DOI https://doi.org/10.2147/BTT.S3914

Review by Single-blind

Peer reviewer comments 2

Andrei Barasch1, Joel Epstein2, Ken Tilashalski1

1Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Oral Medicine and Diagnostic Sciences and Otolaryngology/Head and Neck Surgery, University of Illinois at Chicago, Chicago, IL, USA

Abstract: Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to limited types of patients. The advent of small-molecule targeted agents opened new possibilities for intervention in the mucopathogenic processes induced by cancer therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been studied extensively and has shown promising results in reducing chemotherapy induced OM. This drug’s effects on stem cell engraftment, graft-versus-host disease and other treatment-induced morbidities remain undefined. In this article we evaluate the pre-clinical and clinical evidence and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.

Keywords: mucositis, cancer, therapy, palifermin

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]